Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection

AIDS Research and Human Retroviruses
Pablo TebasWilliam G Powderly

Abstract

In spite of indisputable benefits, the use of antiretroviral therapy is associated with multiple metabolic complications. Switching to simpler regimens might maintain viral suppression, improve metabolic side effects, and provide insight into the pathogenesis of these complications. Our objective was to carefully characterize the virological and metabolic effects of switching from a successful protease inhibitor (PI)-based antiretroviral regimen to a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen with nevirapine (NVP). Forty patients, taking their first successful (less than 40 HIV RNA copies/ml) PI-based regimen, switched their PI to NVP. If patients did not tolerate NVP, substitution with efavirenz was allowed. The duration of the study was 48 weeks. At 12 weeks intervals subjects had multiple virological and metabolic parameters including glucose, insulin, C-peptide, glucagon, proinsulin, blood lipids, and lipoproteins. A subgroup of 18 patients also had body composition evaluations with DEXA scans and MRIs of the abdomen and the thighs as well as insulin tolerance tests. Ninety-five percent of the patients maintained viral suppression (95% CI 88-100%); only one patient failed and another developed hepat...Continue Reading

References

Oct 29, 2000·Lancet·A Carr, D A Cooper
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J Bersoff-MatchaL M Mundy
Oct 2, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·H KnobelUNKNOWN GESIDA 09/99 Study Group
Feb 8, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·W G Powderly
Jul 4, 2002·JAMA : the Journal of the American Medical Association·Andrew CarrUNKNOWN Mitochondrial Toxicity (MITOX) Study Group
Nov 1, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Henning Drechsler, William G Powderly
Nov 20, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Morris SchambelanUNKNOWN International AIDS Society-USA
Jun 7, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Julio S G MontanerUNKNOWN 1100.1286 Study Team
Sep 12, 2003·The New England Journal of Medicine·Esteban MartínezUNKNOWN Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team

❮ Previous
Next ❯

Citations

Feb 2, 2006·Current Infectious Disease Reports·Colleen Hadigan
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valerianna Amorosa, Pablo Tebas
Oct 24, 2008·BMC Infectious Diseases·M Isabel Gonzalez-TomePablo Martin Fontelos
Jul 28, 2009·HIV Clinical Trials·Leigh Anne RedhageTodd Hulgan
Dec 1, 2009·Joint, Bone, Spine : Revue Du Rhumatisme·Julien PaccouBernard Cortet
Apr 29, 2010·Current Rheumatology Reports·Amy H Warriner, Michael J Mugavero
Oct 11, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Denise L JacobsonIra B Wilson
Nov 29, 2007·Wiener klinische Wochenschrift·Janez TomazicLudvik Vidmar
Oct 25, 2006·Journal of Enzyme Inhibition and Medicinal Chemistry·Osmond J D'Cruz, Fatih M Uckun
Jun 6, 2007·Clinical Endocrinology·Mark J BollandIan R Reid
Feb 18, 2011·Enfermedades infecciosas y microbiología clínica·Pere Domingo, Fernando Lozano
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Oriol ManuelPhilip E Tarr
May 21, 2010·Arquivos brasileiros de endocrinologia e metabologia·Erico Higino de CarvalhoMaria da Fátima Pessoa Militão de Albuquerque
Jul 1, 2008·Journal of Midwifery & Women's Health·Julie WomackAnn Williams
Jul 1, 2007·Current Opinion in HIV and AIDS·Patrick W G Mallon
Oct 11, 2007·The Journal of Clinical Endocrinology and Metabolism·Mark J BollandIan R Reid

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.